Which should you choose? Here's what you need to know.
Retatrutide adds a third receptor (glucagon) on top of what tirzepatide does. It's newer and less proven, but early trial data is impressive.
Retatrutide is a triple agonist — GLP-1, GIP, and glucagon — representing the newest generation. Phase 2 trials show it may outperform dual agonists for weight loss.
Choose Retatrutide if:
You want maximum weight loss potential and are okay with a less-proven compound.
Tirzepatide is a dual GIP/GLP-1 agonist that's already FDA-approved as Mounjaro and Zepbound. It has strong clinical data showing up to 22.5% weight loss.
Choose Tirzepatide if:
You want an FDA-approved option with robust clinical trial data and real-world use.
Once you've decided which peptide fits your needs, here's how they compare on price and vendor options.
Our top-rated vendor for each, based on trust scores, purity testing, and price.
We re-check vendor prices continuously and score vendors on Finnrick blind-test results — samples bought anonymously and sent to a lab, not vendor claims. No vendor can pay to rank higher. See our full methodology.